Safety and efficacy of apremilast in pediatric patients with moderate to severe plaque psoriasis: Results from a phase 2 open-label study

doi:10.1016/j.jaad.2019.06.455

Safety and efficacy of apremilast in pediatric patients with moderate to severe plaque psoriasis: Results from a phase 2 open-label study

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2019.06.455 ◽

2019 ◽

Vol 81 (4) ◽

pp. AB120

Keyword(s):

Plaque Psoriasis ◽

Pediatric Patients ◽

Phase 2 ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Safety And Efficacy ◽

Severe Plaque Psoriasis

Download Full-text

Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: Results from a phase 2 open-label study

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2019.08.019 ◽

2020 ◽

Vol 82 (2) ◽

pp. 389-397 ◽

Cited By ~ 7

Author(s):

Amy S. Paller ◽

Ying Hong ◽

Emily M. Becker ◽

Raul de Lucas ◽

Maria Paris ◽

...

Keyword(s):

Plaque Psoriasis ◽

Pediatric Patients ◽

Phase 2 ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Severe Plaque Psoriasis

Download Full-text

A long-term, open-label study of the safety and efficacy of oral tazarotene in moderate to very severe plaque psoriasis

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2003.10.012 ◽

2004 ◽

Vol 50 (3) ◽

pp. P2 ◽

Cited By ~ 1

Author(s):

Alan Menter ◽

Deborah Lew-Kaya ◽

Frederick Beddingfield ◽

Patricia S. Walker

Keyword(s):

Plaque Psoriasis ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Safety And Efficacy ◽

Severe Plaque Psoriasis

Download Full-text

Long‐term safety and efficacy of a fixed‐combination halobetasol propionate 0.01%/tazarotene 0.045% lotion in moderate‐to‐severe plaque psoriasis: phase 3 open‐label study

Journal of the European Academy of Dermatology and Venereology ◽

10.1111/jdv.17113 ◽

2021 ◽

Author(s):

M.G. Lebwohl ◽

L. Stein Gold ◽

K. Papp ◽

G. Han ◽

D.M. Pariser ◽

...

Keyword(s):

Plaque Psoriasis ◽

Fixed Combination ◽

Open Label ◽

Phase 3 ◽

Open Label Study ◽

Label Study ◽

Safety And Efficacy ◽

Severe Plaque Psoriasis

Download Full-text

Results of a phase 2, multicenter, single‐arm, open‐label study of lenalidomide in pediatric patients with relapsed or refractory acute myeloid leukemia

Pediatric Blood & Cancer ◽

10.1002/pbc.28946 ◽

2021 ◽

Author(s):

Maureen M. O'Brien ◽

Todd A. Alonzo ◽

Todd M. Cooper ◽

John E. Levine ◽

Patrick A. Brown ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

Myeloid Leukemia ◽

Pediatric Patients ◽

Phase 2 ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Refractory Acute Myeloid Leukemia ◽

Acute Myeloid

Download Full-text

Safety and Tolerability of Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% (HP/TAZ) Lotion in Patients With Moderate-to-Severe Plaque Psoriasis: Results From a 1-Year, Open-Label Study

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.4.supp.38 ◽

2020 ◽

Vol 4 (5) ◽

pp. s38

Author(s):

Mark G Lebwohl ◽

Jeffrey Sugarman ◽

David M Pariser ◽

Jerry Bagel ◽

Cynthia Trickett ◽

...

Keyword(s):

Plaque Psoriasis ◽

Fixed Combination ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Severe Plaque Psoriasis

Abstract not available.

Download Full-text

Safety and efficacy of switching to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with renal impairment: week 48 results from a phase 2 open label study

Journal of Hepatology ◽

10.1016/s0168-8278(20)32176-0 ◽

2020 ◽

Vol 73 ◽

pp. S868-S869

Author(s):

Harry Janssen ◽

Pietro Lampertico ◽

Chi-Yi Chen ◽

Jeong Heo ◽

Claire Fournier ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis B ◽

Renal Impairment ◽

Chronic Hepatitis B ◽

Phase 2 ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Safety And Efficacy ◽

Tenofovir Alafenamide

Download Full-text

Combined treatment with low-dose cyclosporine and calcipotriol/betamethasone dipropionate ointment for moderate-to-severe plaque psoriasis: a randomized controlled open-label study

Journal of Dermatological Treatment ◽

10.3109/09546634.2011.565017 ◽

2011 ◽

Vol 23 (4) ◽

pp. 255-260 ◽

Cited By ~ 12

Author(s):

Gino A. Vena ◽

Antonia Galluccio ◽

Michele Pezza ◽

Michelangelo Vestita ◽

Nicoletta Cassano

Keyword(s):

Plaque Psoriasis ◽

Low Dose ◽

Combined Treatment ◽

Betamethasone Dipropionate ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Severe Plaque Psoriasis ◽

Randomized Controlled ◽

Calcipotriol Betamethasone

Download Full-text

Open-label study of etanercept treatment in patients with moderate-to-severe plaque psoriasis who lost a satisfactory response to adalimumab

British Journal of Dermatology ◽

10.1111/bjd.15381 ◽

2017 ◽

Vol 177 (2) ◽

pp. 411-418 ◽

Cited By ~ 4

Author(s):

J. Bagel ◽

S. Tyring ◽

K.C. Rice ◽

D.H. Collier ◽

G. Kricorian ◽

...

Keyword(s):

Plaque Psoriasis ◽

Open Label ◽

Etanercept Treatment ◽

Open Label Study ◽

Label Study ◽

Severe Plaque Psoriasis ◽

Satisfactory Response

Download Full-text

A Phase 2, Open-Label Study of the Safety and Efficacy of Intravenous Anidulafungin as a Treatment for Azole-Refractory Mucosal Candidiasis

JAIDS Journal of Acquired Immune Deficiency Syndromes ◽

10.1097/qai.0b013e31817af47a ◽

2008 ◽

Vol 48 (3) ◽

pp. 304-309 ◽

Cited By ~ 40

Author(s):

José A Vazquez ◽

Jennifer A Schranz ◽

Kay Clark ◽

Beth P Goldstein ◽

Annette Reboli ◽

...

Keyword(s):

Phase 2 ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Safety And Efficacy ◽

Mucosal Candidiasis

Download Full-text

A phase 2, open‐label study of single‐dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy

Journal of the European Academy of Dermatology and Venereology ◽

10.1111/jdv.16928 ◽

2020 ◽

Author(s):

A.S. Paller ◽

E.C. Siegfried ◽

E.L. Simpson ◽

M.J. Cork ◽

B. Lockshin ◽

...

Keyword(s):

Atopic Dermatitis ◽

Single Dose ◽

Phase 2 ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Safety And Efficacy

Download Full-text